share_log

Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $110 Price Target

Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $110 Price Target

坎托·菲茨杰拉德重申增持Biomarin Pharmaceutical,维持110美元的目标股价
Benzinga ·  04/25 10:34

Cantor Fitzgerald analyst Olivia Brayer reiterates Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $110 price target.

坎托·菲茨杰拉德分析师奥利维亚·布雷耶重申Biomarin Pharmaceutical(纳斯达克股票代码:BMRN)增持,目标股价维持在110美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发